Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,351 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Glioblastoma, Glioma Clear all
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

NCT01353625
View directory record Official record
Conditions
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions
CC-115
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Children With Primary Malignant Brain Tumors

NCT00003476
View directory record Official record
Conditions
Childhood Brain Tumor
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
6 Months to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 14, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

NCT03197506
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide, Therapeutic Conventional Surgery
Radiation · Other · Biological + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
3
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas

NCT02343406
View directory record Official record
Conditions
Glioblastoma
Interventions
Depatuxizumab mafodotin, Temozolomide, Lomustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 99 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 14, 2026, 9:03 AM EDT
Not listed Phase 1 Interventional

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors

NCT00002647
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions
verteporfin, conventional surgery
Drug · Procedure
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma

NCT00017147
View directory record Official record
Conditions
Malignant Neoplasms of Eye, Brain and Other Parts of Central Nervous System
Interventions
carmustine, radiation therapy, O6-Benzylguanine
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
163
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fairfield, California + 105 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional

Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma

NCT02530502
View directory record Official record
Conditions
Adult Glioblastoma
Interventions
Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy, Temozolomide
Other · Biological · Radiation + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional

Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme

NCT00730262
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
TLN-4601
Drug
Lead sponsor
Thallion Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors

NCT01682746
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin (porfimer sodium) & photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
6 Months to 18 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

NCT02238496
View directory record Official record
Conditions
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
Interventions
Cytoreductive surgery, Perifosine, Temsirolimus
Procedure · Drug
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Evaluation of the CONVIVO System

NCT05139277
View directory record Official record
Conditions
Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
Interventions
CONVIVO system, Conventional histologic evaluation
Diagnostic Test · Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR

NCT05054400
View directory record Official record
Conditions
Brain Metastases, Cancer, Gliomas, Glioblastoma
Interventions
F18 Fluciclovine, Standard of Care
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma

NCT01342757
View directory record Official record
Conditions
Adult Glioblastoma, Depression, Recurrent Adult Brain Tumor
Interventions
vorinostat, temozolomide, magnetic resonance spectroscopic imaging, survey administration
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 14, 2026, 9:03 AM EDT
Active, not recruiting Phase 1 Interventional

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

NCT07031765
View directory record Official record
Conditions
Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV Astrocytoma
Interventions
exHSC, Nivolumab, Resection or biopsy
Biological · Drug · Procedure
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 26 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)

NCT04699773
View directory record Official record
Conditions
Glioma, Glioblastoma, Brain Tumor
Interventions
LITT, Hypofractionated Radiation Therapy
Procedure · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG

NCT03973918
View directory record Official record
Conditions
High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
Interventions
Encorafenib, Binimetinib, Research Bloods, Tumor Tissue
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma

NCT00006024
View directory record Official record
Conditions
Brain Tumor, Central Nervous System Tumor
Interventions
lomustine, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
206
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors

NCT01111097
View directory record Official record
Conditions
Brain Tumor, Glioblastoma
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

NCT07003542
View directory record Official record
Conditions
Glioblastoma, Brain Tumor
Interventions
Sitagliptin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Oct 14, 2026, 9:03 AM EDT
Recruiting Phase 1 Interventional

BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma

NCT04903795
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma, Recurrent Glioblastoma
Interventions
hEGFRvIII-CD3 (BRiTE)
Drug
Lead sponsor
Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 14, 2026, 9:03 AM EDT
Withdrawn Phase 2 Interventional

A Panobinostat Presurgery

NCT01115036
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
panobinostat
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 14, 2026, 9:03 AM EDT
Completed Phase 1 Interventional

ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00770471
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
temozolomide, veliparib, DNA methylation analysis, gene expression analysis, mutation analysis, proteomic profiling, high performance liquid chromatography, immunoenzyme technique, laboratory biomarker analysis, mass spectrometry, pharmacogenomic studies, pharmacological study, adjuvant therapy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 14, 2026, 9:03 AM EDT